Addendum to the Public Announcement for the Buyback of equity shares
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty 100 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences has issued an addendum revising the terms of its ongoing buyback offer. The Buyback Committee has increased the buyback price from INR 1,150 to INR 1,260 per equity share (a 9.6% increase) and reduced the maximum number of shares to be bought back from 95,65,217 to 87,30,158 shares (approximately 0.87% of paid-up capital). The total buyback size remains approximately INR 1,100 crore. The changes were approved on May 27, 2026, pursuant to Regulation 5(via) of the SEBI Buyback Regulations. An addendum to the Public Announcement will be published in major newspapers and on the company and SEBI websites.
The higher buyback price of INR 1,260 is positive for shareholders as it offers greater value per share. The reduced number of shares means fewer shares will be extinguished, potentially having a smaller positive impact on per-share metrics. Overall, this signals the company's confidence in its valuation and provides an attractive exit opportunity at a premium to market prices.